Table 1.

Results of Cost-Effectiveness Analyses Between Clopidogrel and Aspirin Monotherapy

	Costs	Incremental Costs	Effectiveness	Incremental Effectiveness	ICER
Korean health care system perspective
Aspirin	14,451	–	12.447	–	Dominant
Clopidogrel	17,643	3,192	12.309	–0.139	Dominated
UK health care system perspective
Aspirin	7,371	1,122	13.492	0.103	10,931
Clopidogrel	6,249	–	13.390	–	–
U.S. health care system perspective
Aspirin	112,915	8,920	15.280	0.175	50,933
Clopidogrel	103,996	–	15.105	–	–

For the analyses from the South Korean and U.S. health care system perspectives, the unit of the costs was the U.S. dollar. For the analysis from the UK health care system perspective, the unit of the cost was the British pound. For all analyses, the unit of effectiveness was quality-adjusted life-year. Incremental cost-effectiveness ratio (ICER) was defined as incremental costs/quality-adjusted life-year gained.